nanobody antibody-drug conjugate

The nanobody antibody-drug conjugate is a preclinical-stage therapeutic candidate being developed by the National Institute of Diagnostics (NIDVD) at Xiamen University. This agent utilizes a nanobody—a small, single-domain antibody fragment (VHH) typically derived from camelids—to target specific antigens on solid tumor cells. The nanobody is conjugated to a cytotoxic payload, which is released upon binding and internalization, leading to targeted cell death. Nanobody-based ADCs are designed to overcome the limitations of traditional monoclonal antibody-based ADCs, such as poor tissue penetration and complex manufacturing, by leveraging the smaller size and high stability of the VHH domain.

Other names

nanobody-based antibody-drug conjugate